Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Rang in aandelen #25853
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Aandeelprijs
$15.31
Laatst gesynchroniseerd: 2024-02-29
Marktkapitalisatie
$45.70M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Icosavax, Inc. (ICVX)

Categorie

Koersgeschiedenis voor Icosavax, Inc. (ICVX)
Hoogste slotkoers: $15.31 op 2024-02-01

Laagste slotkoers: $29.91 op 2021-07-01
Koersgeschiedenis van Icosavax, Inc. van 2021 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2024 10.83%
2023 104.14%
2022 -70.48%
2021 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$539.14 36.71%
US
$1.04K 56.86%
NL
$120.74 -14.98%
AU
$761.87 7.04%
CH
$130.43 385.07%
US